Request Demo
Last update 12 Oct 2026
SHR-2173
Last update 12 Oct 2026
Overview
Basic Info
Drug Type Fusion protein |
Synonyms Anti-IFNAR1/ TACI fusion protein(Jiangsu Hengrui Pharmaceutical), SHR-2173 |
Target |
Action antagonists, inhibitors |
Mechanism IFNAR-1 antagonists(Interferon-alpha/beta receptor alpha chain antagonists), TNFRSF13B inhibitors(Tumor necrosis factor receptor superfamily member 13B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
9
Clinical Trials associated with SHR-2173NCT07622342
A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of SHR-2173 in Patients With Generalized Myasthenia Gravis
NCT07299422
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Systemic Lupus Erythematosus
NCT07354932
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Primary IgA Nephropathy
100 Clinical Results associated with SHR-2173
Login to view more data
100 Translational Medicine associated with SHR-2173
Login to view more data
100 Patents (Medical) associated with SHR-2173
Login to view more data
100 Deals associated with SHR-2173
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Myasthenia Gravis | Phase 2 | China | 21 May 2026 | |
| Glomerulonephritis, IGA | Phase 2 | China | 09 Mar 2026 | |
| Idiopathic Membranous Glomerulonephritis | Phase 2 | China | 31 Dec 2025 | |
| Lupus Nephritis | Phase 2 | China | 22 Nov 2025 | |
| Purpura, Thrombocytopenic, Idiopathic | Phase 1 | China | 12 Nov 2025 | |
| Sjogren's Syndrome | IND Approval | China | 09 Oct 2026 | |
| Autoimmune Diseases | Preclinical | China | 15 May 2025 | |
| Inflammation | Preclinical | China | 15 May 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 30 | hoadszfubh(hwixvcmvdj) = qhgcygkfzi diitevkprg (qvrfqazwhc ) View more | Positive | 11 Jun 2026 | |||
xomkofkslq(vqvjstzpay) = rshvctdvun xxotjrvojg (tefpbwsxza ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free